Insmed Overview
- Year Founded
-
1988
- Status
-
Public
- Employees
-
1,664
- Stock Symbol
-
INSM
- Investments
-
7
- Share Price
-
$141.33
- (As of Friday Closing)
Insmed General Information
Description
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Contact Information
Website
www.insmed.comCorporate Office
- 700 US Highway 202/206
- Bridgewater, NJ 08807
- United States
Corporate Office
- 700 US Highway 202/206
- Bridgewater, NJ 08807
- United States
Insmed Stock Performance
As of 20-Nov-2026, Insmed’s stock price is $141.33. Its current market cap is $31B with 219M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $141.33 | $144.46 | $90.39 - $212.75 | $31B | 219M | 3.06M | -$2.82 |
Insmed Financials Summary
As of 30-Sep-2026, Insmed has a trailing 12-month revenue of $1.52B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 24,345,634 | 36,014,410 | 11,883,404 | 4,844,741 |
| Revenue | 1,519,721 | 606,423 | 363,707 | 305,208 |
| EBITDA | (498,129) | (1,177,770) | (820,936) | (662,038) |
| Net Income | (605,609) | (1,276,775) | (913,772) | (749,567) |
| Total Assets | 2,226,056 | 2,264,558 | 2,025,231 | 1,329,837 |
| Total Debt | 584,705 | 586,671 | 1,148,877 | 1,203,994 |
Insmed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Insmed Comparisons
Industry
Financing
Details
Insmed Competitors (90)
One of Insmed’s 90 competitors is Ardelyx, a Formerly VC-backed company based in Waltham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ardelyx | Formerly VC-backed | Waltham, MA | ||||
| Titan Pharmaceuticals | Corporation | New York, NY | ||||
| Citius Pharma | Formerly Angel backed | Cranford, NJ | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Rallybio | Formerly VC-backed | New Haven, CT |
Insmed Patents
Insmed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026156112-A1 | Dpp1 inhibitors for use in medicine | Pending | 16-Jan-2025 | ||
| WO-2026148258-A2 | Dipeptidyl peptidase 1 inhibitors and uses thereof | Pending | 03-Jan-2025 | ||
| WO-2026148258-A3 | Dipeptidyl peptidase 1 inhibitors and uses thereof | Pending | 03-Jan-2025 | ||
| WO-2026136275-A1 | Dipeptidyl peptidase 1 inhibitors and uses thereof | Pending | 16-Dec-2024 | ||
| WO-2026107326-A1 | Synthesis of brensocatib((2s)-n-((1s)-1-cyano-2-(4-(3-methyl-2-oxo-2,3 -dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide) | Pending | 15-Nov-2024 | C07D413/12 |
Insmed Signals
Insmed Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Insmed Acquisitions (7)
Insmed’s most recent deal was a Merger/Acquisition with Opsidio for . The deal was made on 01-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Opsidio | 01-Dec-2025 | Merger/Acquisition | Drug Discovery | ||
| Insmed Innovation | 30-Jun-2023 | Merger/Acquisition | Drug Discovery | ||
| Vertuis Bio | 06-Jan-2023 | Merger/Acquisition | Drug Discovery | ||
| AlgaeneX | 04-Aug-2021 | Merger/Acquisition | Drug Discovery | ||
| Motus Biosciences | 04-Aug-2021 | Merger/Acquisition | Discovery Tools (Healthcare) |
Insmed ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
24.15 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Insmed Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| AlgaeneX | San Diego, CA | 2020 |
Insmed FAQs
-
When was Insmed founded?
Insmed was founded in 1988.
-
Where is Insmed headquartered?
Insmed is headquartered in Bridgewater, NJ.
-
What is the size of Insmed?
Insmed has 1,664 total employees.
-
What industry is Insmed in?
Insmed’s primary industry is Biotechnology.
-
Is Insmed a private or public company?
Insmed is a Public company.
-
What is Insmed’s stock symbol?
The ticker symbol for Insmed is INSM.
-
What is the current stock price of Insmed?
As of 20-Nov-2026 the stock price of Insmed is $141.33.
-
What is the current market cap of Insmed?
The current market capitalization of Insmed is $31B.
-
What is Insmed’s current revenue?
The trailing twelve month revenue for Insmed is $1.52B.
-
Who are Insmed’s competitors?
Ardelyx, Titan Pharmaceuticals, Citius Pharma, Arrowhead Pharmaceuticals, and Rallybio are some of the 90 competitors of Insmed.
-
What is Insmed’s annual earnings per share (EPS)?
Insmed’s EPS for 12 months was -$2.82.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process